Pharma Marketing Network

MAY 11, 2021

She has played a key role in helping brands transition from traditional tactical mindsets, to multichannel thinking, and, over time, to omnichannel, data-rich approaches. The post Carol Patel appeared first on Pharma Marketing Network.

Dermatology 52

Dermatology Branding Marketing Development 52

pharmaphorum

FEBRUARY 3, 2021

For the last three years he has served as executive vice president, growth markets commercial, at Israeli pharma Teva. Almirall was in a tricky position when Guenter took over in 2017, hit by generic competition to key US antibiotic brand Acticlate (doxycycline hyclate) and an underperforming medical aesthetics business.

Dermatology 52

Dermatology Marketing Branding Medicine 52

XTalks

DECEMBER 15, 2020

In the deal, Synteract’s brand will remain intact but it will operate as a Syneos Health Business Unit, continued to be led by a strong management team that includes current Synteract President Steve Powell.

Dermatology 98

Dermatology Clinical Trials Clinical Trials Branding 98

XTalks

JUNE 17, 2024

Hugel, a Korean medical aesthetics company, recently announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its botulinum toxin, Letybo (letibotulinumtoxinA-wlbg), for the treatment of glabellar lines. We are thrilled with the FDA’s approval of Letybo. “We What Is the Price of Letybo?

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

Pharma Marketing Network

MARCH 3, 2025

Introduction Pharma marketing has evolved. But how can pharma brands optimize their digital assets while staying compliant with industry regulations? This guide explores CRO best practices , helping pharma marketers maximize HCP and patient engagement while ensuring compliance.

Branding 52

Branding Compliance Marketing Dermatology 52

pharmaphorum

SEPTEMBER 2, 2022

The FDA has cleared the IL-36 receptor inhibitor under the Spevigo brand name to treat the devastating eruptions of painful blisters, known as flares, that are a characteristic of GPP. Spevigo is the first approved therapy for GPP, and the first drug in the IL-36 inhibitor class to make it through development and onto the market.

Drugs 105

Drugs Antibody FDA Approval Trials 105

The Pharma Data

JANUARY 3, 2021

The company’s product brands, such as Artuvetrin, Otodine, Clorexyderm, LinkSkin and SOLO, will remain unchanged. As part of our continued expansion and business development, we and the leadership team are very excited to renew our corporate branding. 4, 2021 11:00 UTC.

Dermatology 40

Dermatology Allergies Branding Business Development 40

Pharma Marketing Network

APRIL 4, 2022

The American Academy of Dermatology (AAD) held its annual conference last weekend, and it was my privilege to be in attendance. As COVID-19 had put the brakes on the show for the past two years, that same sentiment was shared by most of the attendees and exhibitors this year.

Dermatology 52

Dermatology Cosmetics Pharma Companies Branding 52

Druggist

DECEMBER 9, 2020

Clobetasone (brand name: Eumovate cream). Clobetasone (brand name: Eumovate) is the second steroid cream on the list, which is available over the counter. Best selling bite and sting brand Triple action against pain, itching and inflammation Relief from insect bites, insect stings and stinging nettles. Antihistamine creams.

Pharmacy 97

Pharmacy Containment Sales Production 97

XTalks

DECEMBER 15, 2020

In the deal, Synteract’s brand will remain intact but it will operate as a Syneos Health Business Unit, continued to be led by a strong management team that includes current Synteract President Steve Powell.

Dermatology 52

Dermatology Clinical Trials Clinical Trials Branding 52

The Pharma Data

FEBRUARY 5, 2021

CoolSculpting ® has been an industry-leader, creating the market for non-invasive fat reduction over 10 years ago. American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. “The number one aesthetic concern for consumers is excess body fat 1.

Dermatology 52

Dermatology Cosmetics Allergies Production 52

pharmaphorum

OCTOBER 28, 2020

Sanofi sees plenty of additional upside, suggesting the drug could become a $10 billion brand at peak from expansion in atopic dermatitis as well as new indications like asthma, chronic rhinosinusitis with nasal polyps and eosinophilic oesophagitis.

Drugs 52

Drugs Sales Marketing FDA Approval 52

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

pharmaphorum

APRIL 26, 2021

There are already three IL-17 inhibitors on the market, which mainly target IL-17A, Cosentyx (secukinumab) first to get approval for psoriasis in 2015, with Eli Lilly reaching the market in 2016 with Taltz (ixekizumab) followed by Bausch Health’s Siliq (brodalumab) the following year. billion in sales last year.

Antibody 52

Antibody Drugs Marketing Licensing 52

Delveinsight

AUGUST 25, 2021

Pharmaceutical companies may deal in both generic and brand-name drugs as well as medical devices. They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing. . billion followed by the other sectors such as Immunology, Hepatology, and Dermatology (USD 4.86

Vaccination 98

Vaccination Vaccine Drugs Sales 98

pharmaphorum

SEPTEMBER 29, 2022

Sanofi and Regeneron have predicted that Dupixent could make around $13 billion a year at peak, which would propel the drug into the top five biggest pharmaceutical sellers behind brands like AbbVie’s immunology blockbuster Humira (adalimumab), Merck & Co’s cancer immunotherapy Keytruda (pembrolizumab), and COVID-19 vaccines.

Drugs 69

Drugs Immune Response Allergies Sales 69

XTalks

DECEMBER 20, 2023

And this year Eli Lilly stepped into the obesity drug market with its own GLP-1 weight loss drug Zepbound (tirzepatide), which the US Food and Drug Administration (FDA) approved in November of this year. report indicating that they accounted for half of the most viewed new brands. billion ad impressions.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

Pharma Marketing Network

OCTOBER 27, 2020

Don ( PMN): Hello everyone welcome to the Pharma marketing podcast. Robin also coaches people who want to become thought leaders to drive their marketing, personal branding and career advancements. Robin welcome to the Pharma marketing podcast and thanks for joining us today. Don ( PMN): Okay, great advice.

Insulin 52

Insulin Marketing Doctor Doctors 52

The Pharma Data

DECEMBER 15, 2020

Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall in the U.S. Klisyri will be manufactured by Athenex, highlighting the vertically integrated capabilities of the company ranging from a preclinical lead to a developed product for market launch. and in Europe.

FDA Approval 52

FDA Approval Development Production Drugs 52

The Pharma Data

MAY 18, 2021

Our Crop Science Division achieved encouraging sales growth in an improved market environment. This business also expanded in Asia/Pacific as the market situation normalized following the previous year’s restrictions related to the COVID-19 pandemic. to 1.252 billion euros in a declining market. percent (Fx & portfolio adj.)

Sales 40

Sales Production Marketing Containment 40

Pharma Marketing Network

OCTOBER 27, 2020

Don ( PMN): Hello everyone welcome to the Pharma marketing podcast. Robin also coaches people who want to become thought leaders to drive their marketing, personal branding and career advancements. Robin welcome to the Pharma marketing podcast and thanks for joining us today. Don ( PMN): Okay, great advice.

Insulin 52

Insulin Doctor Doctors Marketing 52

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Growth was offset by declines in Established Medicines and mature Ophthalmology brands. Adakveo sales reached USD 37 million. Tafinlar + Mekinist.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

AUGUST 3, 2021

New-to-brand prescription (NBRx) volumes grew 10% year-over-year, even as patient visits to dermatologists remained 15% below pre-pandemic levels. We expect that recovery in the dermatology segment will continue to progress over the coming quarters. In the U.S., Otezla continued to maintain first-line share leadership in psoriasis.

Sales 52

Sales Production Antibody Development 52

Delveinsight

AUGUST 13, 2020

Approval History: In September 2017, FF/UMEC/VI was approved in the US under the brand name Trelegy Ellipta for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm or for the treatment of asthma.

Antibody 40

Antibody Medicine Trials Development 40

Intouch Solutions

OCTOBER 20, 2021

As healthcare marketers, our work is frequently the only mass representation of chronic conditions in advertising. As marketers, we may make a distinction between OTC and Rx when it comes to advertising, but consumers may not, so it can be useful to see how others are successfully marketing in condition-adjacent categories.

Marketing 52

Marketing Dermatology Branding Production 52

Pharmaceutical Technology

JANUARY 25, 2023

A GlobalData survey found that researchers judged decentralised trials to be almost twice as suitable in therapies for metabolic disorders and dermatology compared with immunology. Incorporating these innovations is a key priority for pharma brands hoping to stay on the frontier of change.

Clinical Trials 147

Clinical Trials Clinical Trials Trials Research 147

Pharmaceutical Technology

JANUARY 25, 2023

A GlobalData survey found that researchers judged decentralised trials to be almost twice as suitable in therapies for metabolic disorders and dermatology compared with immunology. Incorporating these innovations is a key priority for pharma brands hoping to stay on the frontier of change.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

Pharma Marketing Network

MARCH 19, 2025

Introduction In the highly regulated pharmaceutical industry, audience engagement is more than just a marketing goalit is a necessity for building trust with healthcare professionals (HCPs) and patients. But how can pharma brands create meaningful connections in a digital landscape crowded with content?

Marketing 52

Marketing Branding Compliance Cardiology 52

World of DTC Marketing

SEPTEMBER 28, 2021

SUMMARY: With supplier costs rising, companies representing some of the biggest brands are urging Congress to address drug pricing. Some employers are offering their people free telehealth, and Amazon may be expanding its telehealth efforts. But that still leaves prescription drugs.

Production 37

Production Drugs Dermatology Branding 37